The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
Open accessAbstract
Summary Background: Pembrolizumab has demonstrated superior progression-free survival (PFS) versus chemotherapy in newly-diagnosed MSI-H/dMMR metastatic colorectal cancer (mCRC). However, its impact on overall survival (OS) in this cohort of patients was unknown. Here we present the final OS analysis of KEYNOTE-177. Methods: The phase 3, open-label study involved 193 sites in 23 countries. Patients aged at least 18 years, with Eastern Cooperative Oncology Group performance status of 0 or 1, and who had newly-diagnosed MSI-H/dMMR mCRC were randomized 1:1 in blocks of four per stratum using an interactive voice response system /integrated web response system to intravenous pembrolizumab 200 mg every 3 weeks or to investigator’s choice of intravenous mFOLFOX6 or FOLFIRI every 2 weeks with or without intravenous bevacizumab 5 mg/kg every 2 weeks or intravenous cetuximab (first dose 400 mg/m2, then 250 mg/m2 for every subsequent dose) weekly. Patients receiving chemotherapy could cross over to pembrolizumab for 35 treatments after progression. Dual-primary endpoints were OS and PFS in the intention-to-treat population. KEYNOTE-177 is registered at ClinicalTrials.gov NCT02563002 and is no longer enrolling patients. Findings: Between February 11, 2016 and February 19, 2018, 307 patients were randomized to pembrolizumab (n = 153) or chemotherapy (n = 154). Sixty percent of patients crossed over from chemotherapy to anti-PD-1/anti-PD-L1 therapy (56 patients to on-study pembrolizumab, 37 patients to off-study therapy). At final analysis (median follow-up of 44.5 months [IQR, 39.7–49.8]), the hazard ratio [HR] for OS was 0.74 (95% confidence interval [CI] 0.53–1.03; P=0.0359; median not reached [95% CI 49.2-not reached] versus 36.7 months [95% CI, 27.6-not reached]) with pembrolizumab versus chemotherapy. Superiority of pembrolizumab versus chemotherapy for OS was not demonstrated as the prespecified α of 0.0246 needed for statistical significance was not achieved. The updated HR for PFS was 0.59 (95% CI 0.45–0.79; median 16.5 [95% CI 5.4–38.1] versus 8.2 months [95% CI 6.1–10.2]). Serious adverse events occurred in 62 of 153 (41%) patients who received pembrolizumab and 75 of 143 (52%) patients who received chemotherapy. Grade ≥3 treatment-related adverse events occurred in 33 of 153 (22%) versus 95 of 143 (66%) patients, respectively. Common grade ≥3 adverse events attributed to pembrolizumab were increased alanine aminotransferase, colitis, diarrhea, and fatigue in 3 of 153 (2%) patients each, and to chemotherapy were decreased neutrophil count (24 of 143 [17%] patients), neutropenia (22 of 143 [15%]), diarrhea (14 of 143 [10%]), and fatigue (13 of 143 [9%]). No deaths attributed to pembrolizumab occurred; one death due to intestinal perforation was attributed to chemotherapy. Interpretation: Pembrolizumab versus chemotherapy continued to provide durable antitumor activity, with no significant difference in OS, and fewer treatment-related events. These findings support pembrolizumab as effective first-line therapy in patients with MSI-H/dMMR mCRC. Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Self-citationOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Self-citationMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Fornaro, L., Olesiński, T., Caglevic, C., Chung, H. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31257-1 · Cited by 1,296
Self-citationAnalysis of survival by tumor response.
Anderson, J. R., Cain, K. C., & Gelber, R. D. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.11.710 · Cited by 1,107
Cited by
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Self-citationImmune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Eng, C., Yoshino, T., Ruíz-García, E., Mostafa, N., Cann, C. G., O'Brian, B., Benny, A., Perez, R. O., & Cremolini, C. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00360-x · Cited by 449
Self-citationChao, J., Fuchs, C. S., Shitara, K., Tabernero, J., Muro, K., Van Cutsem, E., Bang, Y.-J., De Vita, F., Landers, G., Yen, C.-J., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0275 · Cited by 443
Ovarian Cancer Immunotherapy and Personalized Medicine
Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., & Nemunaitis, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126532 · Cited by 372
Metadata
- Authors
- Diaz, L. A., Shiu, K.-K., Kim, T.-W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., de la Fourchardiere, C., Rivera, F., Elez, E., Le, D. T., Yoshino, T., Zhong, W. Y., Fogelman, D., Marinello, P., & Andre, T.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 23
- Issue
- 5
- Pages
- 659-670
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4223510971
- Cited by
- 945
- References
- 24
- FWCI
- 66.16
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00197-8
- The paper
- Diaz, L. A., Shiu, K.-K., Kim, T.-W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., de la Fourchardiere, C., Rivera, F., Elez, E., Le, D. T., Yoshino, T., Zhong, W. Y., Fogelman, D., Marinello, P., & Andre, T. (2022). Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00197-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.